Key negotiations that helped seal Gilead Science’s $21 billion purchase of Immunomedics, announced Sunday, took place on the makeshift patio of a suburban New Jersey restaurant during a socially distanced dinner two weeks ago, separated from a highway by some hedges.
Immunomedics’ Executive Chairman Behzad Aghazadeh, eating at a restaurant for the first time since the Covid-19 pandemic struck, ordered lamb chops. Gilead CEO Daniel O’Day had steak. They requested a table away from other diners in order to be discrete. But the main thing on the menu, from Gilead’s perspective, was Trodelvy, Immunomedics’ recently approved drug to treat women with triple-negative breast cancer, a particularly aggressive form of the disease with few treatment options.
What is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
September 14, 2020 at 03:55PM
https://ift.tt/2FsdjrN
Inside Gilead's $21 billion purchase of Immunomedics: Lamb chops - STAT
https://ift.tt/38fhwJ2
Steak
No comments:
Post a Comment